🌱 KidneyEnergy.com

← all stories

Peer reviewed Reversal pharmaceuticalinstitute checked against the paper

a 48-year-old man

Paraneoplastic membranous nephropathy (PLA2R/THSD7A/NELL-1 triple-negative) together with stage IV mantle cell lymphoma

BeforeNephrotic syndrome with proteinuria 7.38 g/24 hours and serum albumin 26.2 g/L
AfterNephrotic syndrome resolved with proteinuria falling to 0.29 g/24 hours and serum albumin rising to 35.5 g/L; both lymphoma and kidney disease stayed in remission for more than 2 years

He was treated for the lymphoma alone with R-CHOP and R-DHAP chemotherapy to start, then an autologous stem cell transplant, and extended rituximab maintenance. Treating the cancer alone brought the kidney disease into remission, with kidney function preserved.

In one man, treating his mantle cell lymphoma alone put his kidney disease into remission too, because the cancer was what was driving the kidney damage.

Key takeaways

Why it might work

The paper frames this kidney disease as paraneoplastic, which means the tumor itself was the cause. His membranous nephropathy tested negative for the usual antibody targets (PLA2R, THSD7A, and NELL-1), so it was not one of the more common antibody-driven forms. When the lymphoma is the engine behind the kidney injury, removing or shrinking the cancer removes the cause, and the kidney can recover on its own. That is why the doctors treated the lymphoma with chemotherapy, a stem cell transplant, and rituximab maintenance, and the kidney disease settled down as the cancer went into remission.

The honest limits

Questions to bring your nephrologist

Researchers: Lv D · Sun P · Li Y · Liu T · Ye F · Yu Y · Li T · Liu A

PubMed ↗added 2026-08-15